IL2 and neoplasm: Thereafter, antigen-activated and -nonactivated CAR T cells displayed distinct accumulation kinetics: while in the EGFR CAR T cell (± IL-2)-treated cohorts, the first signal emerged at the tumor site, BDCA-2 CAR T cells (± IL-2) primarily homed to the spleen.